163 related articles for article (PubMed ID: 22037253)
21. New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitory activity and selectivity.
Bey E; Marchais-Oberwinkler S; Negri M; Kruchten P; Oster A; Klein T; Spadaro A; Werth R; Frotscher M; Birk B; Hartmann RW
J Med Chem; 2009 Nov; 52(21):6724-43. PubMed ID: 19831396
[TBL] [Abstract][Full Text] [Related]
22. Optimization of hydroxybenzothiazoles as novel potent and selective inhibitors of 17β-HSD1.
Spadaro A; Frotscher M; Hartmann RW
J Med Chem; 2012 Mar; 55(5):2469-73. PubMed ID: 22277094
[TBL] [Abstract][Full Text] [Related]
23. Introduction of an electron withdrawing group on the hydroxyphenylnaphthol scaffold improves the potency of 17β-hydroxysteroid dehydrogenase type 2 (17β-HSD2) inhibitors.
Wetzel M; Marchais-Oberwinkler S; Perspicace E; Möller G; Adamski J; Hartmann RW
J Med Chem; 2011 Nov; 54(21):7547-57. PubMed ID: 21972996
[TBL] [Abstract][Full Text] [Related]
24. Hydroxybenzothiazoles as new nonsteroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1).
Spadaro A; Negri M; Marchais-Oberwinkler S; Bey E; Frotscher M
PLoS One; 2012; 7(1):e29252. PubMed ID: 22242164
[TBL] [Abstract][Full Text] [Related]
25. Development of potential preclinical candidates with promising in vitro ADME profile for the inhibition of type 1 and type 2 17β-Hydroxysteroid dehydrogenases: Design, synthesis, and biological evaluation.
Abdelsamie AS; Salah M; Siebenbürger L; Hamed MM; Börger C; van Koppen CJ; Frotscher M; Hartmann RW
Eur J Med Chem; 2019 Sep; 178():93-107. PubMed ID: 31176098
[TBL] [Abstract][Full Text] [Related]
26. Phenylbenzenesulfonates and -sulfonamides as 17β-hydroxysteroid dehydrogenase type 2 inhibitors: Synthesis and SAR-analysis.
Vuorinen A; Engeli RT; Leugger S; Kreutz CR; Schuster D; Odermatt A; Matuszczak B
Bioorg Med Chem Lett; 2017 Jul; 27(13):2982-2985. PubMed ID: 28506753
[TBL] [Abstract][Full Text] [Related]
27. Type 2 17-β hydroxysteroid dehydrogenase as a novel target for the treatment of osteoporosis.
Soubhye J; Alard IC; van Antwerpen P; Dufrasne F
Future Med Chem; 2015; 7(11):1431-56. PubMed ID: 26230882
[TBL] [Abstract][Full Text] [Related]
28. Estradiol and estrone C-16 derivatives as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: blocking of ER+ breast cancer cell proliferation induced by estrone.
Laplante Y; Cadot C; Fournier MA; Poirier D
Bioorg Med Chem; 2008 Feb; 16(4):1849-60. PubMed ID: 18035543
[TBL] [Abstract][Full Text] [Related]
29. Lead optimization of 17β-HSD1 inhibitors of the (hydroxyphenyl)naphthol sulfonamide type for the treatment of endometriosis.
Henn C; Einspanier A; Marchais-Oberwinkler S; Frotscher M; Hartmann RW
J Med Chem; 2012 Apr; 55(7):3307-18. PubMed ID: 22380653
[TBL] [Abstract][Full Text] [Related]
30. Addressing cytotoxicity of 1,4-biphenyl amide derivatives: Discovery of new potent and selective 17β-hydroxysteroid dehydrogenase type 2 inhibitors.
Gargano EM; Perspicace E; Carotti A; Marchais-Oberwinkler S; Hartmann RW
Bioorg Med Chem Lett; 2016 Jan; 26(1):21-4. PubMed ID: 26615885
[TBL] [Abstract][Full Text] [Related]
31. Design, synthesis and biological evaluation of bis(hydroxyphenyl) azoles as potent and selective non-steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.
Bey E; Marchais-Oberwinkler S; Kruchten P; Frotscher M; Werth R; Oster A; Algül O; Neugebauer A; Hartmann RW
Bioorg Med Chem; 2008 Jun; 16(12):6423-35. PubMed ID: 18514529
[TBL] [Abstract][Full Text] [Related]
32. Metabolic stability optimization and metabolite identification of 2,5-thiophene amide 17β-hydroxysteroid dehydrogenase type 2 inhibitors.
Gargano EM; Perspicace E; Hanke N; Carotti A; Marchais-Oberwinkler S; Hartmann RW
Eur J Med Chem; 2014 Nov; 87():203-19. PubMed ID: 25259513
[TBL] [Abstract][Full Text] [Related]
33. Ligand-based pharmacophore modeling and virtual screening for the discovery of novel 17β-hydroxysteroid dehydrogenase 2 inhibitors.
Vuorinen A; Engeli R; Meyer A; Bachmann F; Griesser UJ; Schuster D; Odermatt A
J Med Chem; 2014 Jul; 57(14):5995-6007. PubMed ID: 24960438
[TBL] [Abstract][Full Text] [Related]
34. Discovery of nonsteroidal 17beta-hydroxysteroid dehydrogenase 1 inhibitors by pharmacophore-based screening of virtual compound libraries.
Schuster D; Nashev LG; Kirchmair J; Laggner C; Wolber G; Langer T; Odermatt A
J Med Chem; 2008 Jul; 51(14):4188-99. PubMed ID: 18533708
[TBL] [Abstract][Full Text] [Related]
35. Novel, potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
Allan GM; Bubert C; Vicker N; Smith A; Tutill HJ; Purohit A; Reed MJ; Potter BV
Mol Cell Endocrinol; 2006 Mar; 248(1-2):204-7. PubMed ID: 16337736
[TBL] [Abstract][Full Text] [Related]
36. 17β-Hydroxysteroid Dehydrogenase Type 2 Inhibition: Discovery of Selective and Metabolically Stable Compounds Inhibiting Both the Human Enzyme and Its Murine Ortholog.
Gargano EM; Allegretta G; Perspicace E; Carotti A; Van Koppen C; Frotscher M; Marchais-Oberwinkler S; Hartmann RW
PLoS One; 2015; 10(7):e0134754. PubMed ID: 26230928
[TBL] [Abstract][Full Text] [Related]
37. Discovery of a non-estrogenic irreversible inhibitor of 17β-hydroxysteroid dehydrogenase type 1 from 3-substituted-16β-(m-carbamoylbenzyl)-estradiol derivatives.
Maltais R; Ayan D; Trottier A; Barbeau X; Lagüe P; Bouchard JE; Poirier D
J Med Chem; 2014 Jan; 57(1):204-22. PubMed ID: 24328103
[TBL] [Abstract][Full Text] [Related]
38. Pharmacophore modelling of 17beta-HSD1 enzyme based on active inhibitors and enzyme structure.
Karkola S; Alho-Richmond S; Wahala K
Mol Cell Endocrinol; 2009 Mar; 301(1-2):225-8. PubMed ID: 18822344
[TBL] [Abstract][Full Text] [Related]
39. Novel estrone mimetics with high 17beta-HSD1 inhibitory activity.
Oster A; Klein T; Werth R; Kruchten P; Bey E; Negri M; Marchais-Oberwinkler S; Frotscher M; Hartmann RW
Bioorg Med Chem; 2010 May; 18(10):3494-505. PubMed ID: 20413314
[TBL] [Abstract][Full Text] [Related]
40. Design, Synthesis, and Biological Characterization of Orally Active 17β-Hydroxysteroid Dehydrogenase Type 2 Inhibitors Targeting the Prevention of Osteoporosis.
Abdelsamie AS; Salah M; Siebenbürger L; Merabet A; Scheuer C; Frotscher M; Müller ST; Zierau O; Vollmer G; Menger MD; Laschke MW; van Koppen CJ; Marchais-Oberwinkler S; Hartmann RW
J Med Chem; 2019 Aug; 62(15):7289-7301. PubMed ID: 31343176
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
